Potential therapeutic applications of differentiated induced pluripotent stem cells (iPSCs) in the treatment of neurodegenerative diseases

Neuroscience

Volumn 228, Issue , 2013, Pages 47-59

  Gao, Aijing ^a   Peng, Yuhua ^a   Deng, Yulin ^a   Qing, Hong ^a  

^a BEIJING INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Cell therapy; Differentiation; Immunogenicity; Induced pluripotent stem cells; Neurodegerative diseases; Reprogramming factors

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALPHA SYNUCLEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; DNA BINDING PROTEIN; HUNTINGTIN; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PRESENILIN 1; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2; TAU PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR LIN 28; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CELL THERAPY; CELL TYPE; DEGENERATIVE DISEASE; EMBRYONIC STEM CELL; HUMAN; HUNTINGTON CHOREA; IMMUNOGENICITY; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; NUCLEAR REPROGRAMMING; PARKINSON DISEASE; PATHOGENESIS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SPINAL MUSCULAR ATROPHY;

ANIMALS; CELL DIFFERENTIATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; NEURODEGENERATIVE DISEASES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84868594756     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.09.076     Document Type: Review

References (101)

1. Ban H., Nishishita N., Fusaki N., Tabata T., Saeki K., Shikamura M., Takada N., Inoue M., Hasegawa M., Kawamata S., Nishikawa S. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci U S A 2011, 108:14234-14239.
2. Baughan T., Shababi M., Coady T.H., Dickson A.M., Tullis G.E., Lorson C.L. Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Mol Ther 2006, 14:54-62.
3. Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994, 330:585-591.
4. Bilican B., Serio A., Barmada S.J., Nishimura A.L., Sullivan G.J., Carrasco M., Phatnani H.P., Puddifoot C.A., Story D., Fletcher J., Park I.H., Friedman B.A., Daley G.Q., Wyllie D.J., Hardingham G.E., Wilmut I., Finkbeiner S., Maniatis T., Shaw C.E., Chandran S. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A 2012, 109:5803-5808.
5. Blesch A., Tuszynski M.H. Gene therapy and cell transplantation for Alzheimer's disease and spinal cord injury. Yonsei Med J 2004, 45(Suppl):28-31.
6. Boue S., Paramonov I., Barrero M.J., Izpisua Belmonte J.C. Analysis of human and mouse reprogramming of somatic cells to induced pluripotent stem cells. What is in the plate?. PLoS One 2010, 5.
7. Brown R.H. Developmental biology. Neuron research leaps ahead. Science 2008, 321:1169-1170.
8. Cai J., Yang M., Poremsky E., Kidd S., Schneider J.S., Iacovitti L. Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. Stem Cells Dev 2010, 19:1017-1023.
9. Camnasio S., Carri A.D., Lombardo A., Grad I., Mariotti C., Castucci A., Rozell B., Riso P.L., Castiglioni V., Zuccato C., Rochon C., Takashima Y., Diaferia G., Biunno I., Gellera C., Jaconi M., Smith A., Hovatta O., Naldini L., Di Donato S., Feki A., Cattaneo E. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis 2012, 46:41-51.
10. Chan A.W., Cheng P.H., Neumann A., Yang J.J. Reprogramming Huntington monkey skin cells into pluripotent stem cells. Cell Reprogram 2010, 12:509-517.
11. Chen T., Shen L., Yu J., Wan H., Guo A., Chen J., Long Y., Zhao J., Pei G. Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell 2011, 10:908-911.
12. Corti O., Lesage S., Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 2011, 91:1161-1218.
13. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122(Pt 8):1437-1448.
14. Desplats P.A., Denny C.A., Kass K.E., Gilmartin T., Head S.R., Sutcliffe J.G., Seyfried T.N., Thomas E.A. Glycolipid and ganglioside metabolism imbalances in Huntington's disease. Neurobiol Dis 2007, 27:265-277.
15. Devine M.J., Ryten M., Vodicka P., Thomson A.J., Burdon T., Houlden H., Cavaleri F., Nagano M., Drummond N.J., Taanman J.W., Schapira A.H., Gwinn K., Hardy J., Lewis P.A., Kunath T. Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat Commun 2011, 2:440.
16. Dezawa M., Ishikawa H., Hoshino M., Itokazu Y., Nabeshima Y. Potential of bone marrow stromal cells in applications for neuro-degenerative, neuro-traumatic and muscle degenerative diseases. Curr Neuropharmacol 2005, 3:257-266.
17. Dimos J.T., Rodolfa K.T., Niakan K.K., Weisenthal L.M., Mitsumoto H., Chung W., Croft G.F., Saphier G., Leibel R., Goland R., Wichterle H., Henderson C.E., Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321:1218-1221.
18. Dion P.A., Daoud H., Rouleau G.A. Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat Rev Genet 2009, 10:769-782.
19. Dunckley T., Huentelman M.J., Craig D.W., Pearson J.V., Szelinger S., Joshipura K., Halperin R.F., Stamper C., Jensen K.R., Letizia D., Hesterlee S.E., Pestronk A., Levine T., Bertorini T., Graves M.C., Mozaffar T., Jackson C.E., Bosch P., McVey A., Dick A., Barohn R., Lomen-Hoerth C., Rosenfeld J., O'Connor D.T., Zhang K., Crook R., Ryberg H., Hutton M., Katz J., Simpson E.P., Mitsumoto H., Bowser R., Miller R.G., Appel S.H., Stephan D.A. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med 2007, 357:775-788.
20. Ebert A.D., Svendsen C.N. Stem cell model of spinal muscular atrophy. Arch Neurol 2010, 67:665-669.
21. Ebert A.D., Yu J., Rose F.F., Mattis V.B., Lorson C.L., Thomson J.A., Svendsen C.N. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457:277-280.
22. Esteban M.A., Wang T., Qin B., Yang J., Qin D., Cai J., Li W., Weng Z., Chen J., Ni S., Chen K., Li Y., Liu X., Xu J., Zhang S., Li F., He W., Labuda K., Song Y., Peterbauer A., Wolbank S., Redl H., Zhong M., Cai D., Zeng L., Pei D. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell 2010, 6:71-79.
23. Feng B., Jiang J., Kraus P., Ng J.H., Heng J.C., Chan Y.S., Yaw L.P., Zhang W., Loh Y.H., Han J., Vega V.B., Cacheux-Rataboul V., Lim B., Lufkin T., Ng H.H. Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb. Nat Cell Biol 2009, 11:197-203.
24. Feng B., Ng J.H., Heng J.C., Ng H.H. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 2009, 4:301-312.
25. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
26. Gomi M., Aoki T., Takagi Y., Nishimura M., Ohsugi Y., Mihara M., Nozaki K., Hashimoto N., Miyamoto S., Takahashi J. Single and local blockade of interleukin-6 signaling promotes neuronal differentiation from transplanted embryonic stem cell-derived neural precursor cells. J Neurosci Res 2011, 89:1388-1399.
27. Gordon P.H. Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management. CNS Drugs 2011, 25:1-15.
28. Hanna J., Cheng A.W., Saha K., Kim J., Lengner C.J., Soldner F., Cassady J.P., Muffat J., Carey B.W., Jaenisch R. Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proc Natl Acad Sci U S A 2010, 107:9222-9227.
29. Hardy J., Gwinn-Hardy K. Genetic classification of primary neurodegenerative disease. Science 1998, 282:1075-1079.
30. Hester M.E., Song S., Miranda C.J., Eagle A., Schwartz P.H., Kaspar B.K. Two factor reprogramming of human neural stem cells into pluripotency. PLoS One 2009, 4:e7044.
31. Huang G., Shigesada K., Ito K., Wee H.J., Yokomizo T., Ito Y. Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J 2001, 20:723-733.
32. Huangfu D., Maehr R., Guo W., Eijkelenboom A., Snitow M., Chen A.E., Melton D.A. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008, 26:795-797.
33. Inoue H. Neurodegenerative disease-specific induced pluripotent stem cell research. Exp Cell Res 2010, 316:2560-2564.
34. Israel M.A., Yuan S.H., Bardy C., Reyna S.M., Mu Y., Herrera C., Hefferan M.P., Van Gorp S., Nazor K.L., Boscolo F.S., Carson C.T., Laurent L.C., Marsala M., Gage F.H., Remes A.M., Koo E.H., Goldstein L.S. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012, 482:216-220.
35. Jandial R., Levy M.L. Cellular alchemy: induced pluripotent stem cells retain epigenetic memory. World Neurosurg 2011, 75:5-6.
36. Jandial R., Singec I., Ames C.P., Snyder E.Y. Genetic modification of neural stem cells. Mol Ther 2008, 16:450-457.
37. Jenner P., Olanow C.W. The pathogenesis of cell death in Parkinson's disease. Neurology 2006, 66:S24-36.
38. Jensen M.B., Yan H., Krishnaney-Davison R., Al Sawaf A., Zhang S.C. Survival and differentiation of transplanted neural stem cells derived from human induced pluripotent stem cells in a rat stroke model. J Stroke Cerebrovasc Dis 2011.
39. Jia F., Wilson K.D., Sun N., Gupta D.M., Huang M., Li Z., Panetta N.J., Chen Z.Y., Robbins R.C., Kay M.A., Longaker M.T., Wu J.C. A nonviral minicircle vector for deriving human iPS cells. Nat Methods 2010, 7:197-199.
40. Joyce N., Annett G., Wirthlin L., Olson S., Bauer G., Nolta J.A. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med 2010, 5:933-946.
41. Kang N.Y., Yun S.W., Ha H.H., Park S.J., Chang Y.T. Embryonic and induced pluripotent stem cell staining and sorting with the live-cell fluorescence imaging probe CDy1. Nat Protoc 2011, 6:1044-1052.
42. Kim J.H., Auerbach J.M., Rodriguez-Gomez J.A., Velasco I., Gavin D., Lumelsky N., Lee S.H., Nguyen J., Sanchez-Pernaute R., Bankiewicz K., McKay R. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002, 418:50-56.
43. Kim M., Lee S.T., Chu K., Kim S.U. Stem cell-based cell therapy for Huntington disease: a review. Neuropathology 2008, 28:1-9.
44. Kim D., Kim C.H., Moon J.I., Chung Y.G., Chang M.Y., Han B.S., Ko S., Yang E., Cha K.Y., Lanza R., Kim K.S. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009, 4:472-476.
45. Klinge P.M., Harmening K., Miller M.C., Heile A., Wallrapp C., Geigle P., Brinker T. Encapsulated native and glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease. Neurosci Lett 2011, 497:6-10.
46. Ku S., Soragni E., Campau E., Thomas E.A., Altun G., Laurent L.C., Loring J.F., Napierala M., Gottesfeld J.M. Friedreich's ataxia induced pluripotent stem cells model intergenerational GAATTC triplet repeat instability. Cell Stem Cell 2010, 7:631-637.
47. Lee G., Papapetrou E.P., Kim H., Chambers S.M., Tomishima M.J., Fasano C.A., Ganat Y.M., Menon J., Shimizu F., Viale A., Tabar V., Sadelain M., Studer L. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009, 461:402-406.
48. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
49. Lehericy S., Hirsch E.C., Cervera-Pierot P., Hersh L.B., Bakchine S., Piette F., Duyckaerts C., Hauw J.J., Javoy-Agid F., Agid Y. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J Comp Neurol 1993, 330:15-31.
50. Lian Q., Zhang Y., Zhang J., Zhang H.K., Wu X., Lam F.F., Kang S., Xia J.C., Lai W.H., Au K.W., Chow Y.Y., Siu C.W., Lee C.N., Tse H.F. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation 2010, 121:1113-1123.
51. Lim H.C., Lee S.T., Chu K., Joo K.M., Kang L., Im W.S., Park J.E., Kim S.U., Kim M., Cha C.I. Neuroprotective effect of neural stem cell-conditioned media in in vitro model of Huntington's disease. Neurosci Lett 2008, 435:175-180.
52. Lister R., Pelizzola M., Kida Y.S., Hawkins R.D., Nery J.R., Hon G., Antosiewicz-Bourget J., O'Malley R., Castanon R., Klugman S., Downes M., Yu R., Stewart R., Ren B., Thomson J.A., Evans R.M., Ecker J.R. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011, 471:68-73.
53. Lorson C.L., Hahnen E., Androphy E.J., Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A 1999, 96:6307-6311.
54. Lutz C.M., Kariya S., Patruni S., Osborne M.A., Liu D., Henderson C.E., Li D.K., Pellizzoni L., Rojas J., Valenzuela D.M., Murphy A.J., Winberg M.L., Monani U.R. Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest 2011, 121:3029-3041.
55. MacDonald M.E., Gusella J.F. Huntington's disease: translating a CAG repeat into a pathogenic mechanism. Curr Opin Neurobiol 1996, 6:638-643.
56. Mali P., Chou B.K., Yen J., Ye Z., Zou J., Dowey S., Brodsky R.A., Ohm J.E., Yu W., Baylin S.B., Yusa K., Bradley A., Meyers D.J., Mukherjee C., Cole P.A., Cheng L. Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem cells 2010, 28:713-720.
57. Marchetto M.C., Yeo G.W., Kainohana O., Marsala M., Gage F.H., Muotri A.R. Transcriptional signature and memory retention of human-induced pluripotent stem cells. PLoS One 2009, 4:e7076.
58. Mathew R., Jia W., Sharma A., Zhao Y., Clarke L.E., Cheng X., Wang H., Salli U., Vrana K.E., Robertson G.P., Zhu J., Wang S. Robust activation of the human but not mouse telomerase gene during the induction of pluripotency. FASEB J 2010, 24:2702-2715.
59. Mattson M.P., Chan S.L. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium 2003, 34:385-397.
60. Mattson M.P., Chan S.L., Duan W. Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol Rev 2002, 82:637-672.
61. Mikkelsen T.S., Hanna J., Zhang X., Ku M., Wernig M., Schorderet P., Bernstein B.E., Jaenisch R., Lander E.S., Meissner A. Dissecting direct reprogramming through integrative genomic analysis. Nature 2008, 454:49-55.
62. Mitne-Neto M., Machado-Costa M., Marchetto M.C., Bengtson M.H., Joazeiro C.A., Tsuda H., Bellen H.J., Silva H.C., Oliveira A.S., Lazar M., Muotri A.R., Zatz M. Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. Hum Mol Genet 2011, 20:3642-3652.
63. Moriguchi H., Chung R.T., Mihara M., Sato C. Generation of human induced pluripotent stem cells from liver progenitor cells by only small molecules. Hepatology 2010, 52:1169. author reply 1169-1170.
64. Oki K., Tatarishvili J., Wood J., Koch P., Wattananit S., Mine Y., Monni E., Tornero D., Ahlenius H., Ladewig J., Brustle O., Lindvall O., Kokaia Z. Human-induced pluripotent stem cells form functional neurons and improve recovery after grafting in stroke-damaged brain. Stem cells 2012, 30:1120-1133.
65. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322:949-953.
66. Okita K., Nagata N., Yamanaka S. Immunogenicity of induced pluripotent stem cells. Circ Res 2011, 109:720-721.
67. Park I.H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., Lensch M.W., Cowan C., Hochedlinger K., Daley G.Q. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
68. Patterson M., Chan D.N., Ha I., Case D., Cui Y., Handel B.V., Mikkola H.K., Lowry W.E. Defining the nature of human pluripotent stem cell progeny. Cell Res 2011, 25:25.
69. Piccini P., Brooks D.J., Bjorklund A., Gunn R.N., Grasby P.M., Rimoldi O., Brundin P., Hagell P., Rehncrona S., Widner H., Lindvall O. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999, 2:1137-1140.
70. Ralph G.S., Radcliffe P.A., Day D.M., Carthy J.M., Leroux M.A., Lee D.C., Wong L.F., Bilsland L.G., Greensmith L., Kingsman S.M., Mitrophanous K.A., Mazarakis N.D., Azzouz M. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005, 11:429-433.
71. Rhee Y.H., Ko J.Y., Chang M.Y., Yi S.H., Kim D., Kim C.H., Shim J.W., Jo A.Y., Kim B.W., Lee H., Lee S.H., Suh W., Park C.H., Koh H.C., Lee Y.S., Lanza R., Kim K.S. Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. J Clin Invest 2011, 121:2326-2335.
72. Ross C.A. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 2002, 35:819-822.
73. Schindowski K., Belarbi K., Buee L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav 2008, 7(Suppl 1):43-56.
74. Si-Tayeb K., Noto F.K., Sepac A., Sedlic F., Bosnjak Z.J., Lough J.W., Duncan S.A. Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev Biol 2010, 10:81.
75. Soldner F., Hockemeyer D., Beard C., Gao Q., Bell G.W., Cook E.G., Hargus G., Blak A., Cooper O., Mitalipova M., Isacson O., Jaenisch R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136:964-977.
76. Sommer C.A., Stadtfeld M., Murphy G.J., Hochedlinger K., Kotton D.N., Mostoslavsky G. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 2009, 27:543-549.
77. Stadtfeld M., Nagaya M., Utikal J., Weir G., Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008, 322:945-949.
78. Sumner C.J. Therapeutics development for spinal muscular atrophy. NeuroRx 2006, 3:235-245.
79. Swistowski A., Peng J., Liu Q., Mali P., Rao M.S., Cheng L., Zeng X. Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. Stem cells 2010, 28:1893-1904.
80. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
81. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
82. Teuling E., Ahmed S., Haasdijk E., Demmers J., Steinmetz M.O., Akhmanova A., Jaarsma D., Hoogenraad C.C. Motor neuron disease-associated mutant vesicle-associated membrane protein-associated protein (VAP) B recruits wild-type VAPs into endoplasmic reticulum-derived tubular aggregates. J Neurosci 2007, 27:9801-9815.
83. Traub R., Mitsumoto H., Rowland L.P. Research advances in amyotrophic lateral sclerosis, 2009 to 2010. Curr Neurol Neurosci Rep 2011, 11:67-77.
84. von Gontard A., Zerres K., Backes M., Laufersweiler-Plass C., Wendland C., Melchers P., Lehmkuhl G., Rudnik-Schoneborn S. Intelligence and cognitive function in children and adolescents with spinal muscular atrophy. Neuromuscul Disord 2002, 12:130-136.
85. Wang A., Tang Z., Park I.H., Zhu Y., Patel S., Daley G.Q., Li S. Induced pluripotent stem cells for neural tissue engineering. Biomaterials 2011, 32:5023-5032.
86. Wang Q., Xu X., Li J., Liu J., Gu H., Zhang R., Chen J., Kuang Y., Fei J., Jiang C., Wang P., Pei D., Ding S., Xie X. Lithium, an anti-psychotic drug, greatly enhances the generation of induced pluripotent stem cells. Cell Res 2011, 21:1424-1435.
87. Warren L., Manos P.D., Ahfeldt T., Loh Y.H., Li H., Lau F., Ebina W., Mandal P.K., Smith Z.D., Meissner A., Daley G.Q., Brack A.S., Collins J.J., Cowan C., Schlaeger T.M., Rossi D.J. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:618-630.
88. Wernig M., Zhao J.P., Pruszak J., Hedlund E., Fu D., Soldner F., Broccoli V., Constantine-Paton M., Isacson O., Jaenisch R. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 2008, 105:5856-5861.
89. Winner B., Kohl Z., Gage F.H. Neurodegenerative disease and adult neurogenesis. Eur J Neurosci 2011, 33:1139-1151.
90. Wirth B., Brichta L., Hahnen E. Spinal muscular atrophy: from gene to therapy. Semin Pediatr Neurol 2006, 13:121-131.
91. Woltjen K., Michael I.P., Mohseni P., Desai R., Mileikovsky M., Hamalainen R., Cowling R., Wang W., Liu P., Gertsenstein M., Kaji K., Sung H.K., Nagy A. PiggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009, 458:766-770.
92. Wu S.M., Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol 2011, 13:497-505.
93. Xu L., Tan Y.Y., Ding J.Q., Chen S.D. The iPS technique provides hope for Parkinson's disease treatment. Stem Cell Rev 2010, 6:398-404.
94. Xuan A.G., Luo M., Ji W.D., Long D.H. Effects of engrafted neural stem cells in Alzheimer's disease rats. Neurosci Lett 2009, 450:167-171.
95. Yamanaka S., Blau H.M. Nuclear reprogramming to a pluripotent state by three approaches. Nature 2010, 465:704-712.
96. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., Slukvin I.I., Thomson J.A. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
97. Zerres K., Wirth B., Rudnik-Schoneborn S. Spinal muscular atrophy-clinical and genetic correlations. Neuromuscul Disord 1997, 7:202-207.
98. Zhao Y., Yin X., Qin H., Zhu F., Liu H., Yang W., Zhang Q., Xiang C., Hou P., Song Z., Liu Y., Yong J., Zhang P., Cai J., Liu M., Li H., Li Y., Qu X., Cui K., Zhang W., Xiang T., Wu Y., Liu C., Yu C., Yuan K., Lou J., Ding M., Deng H. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 2008, 3:475-479.
99. Zhao X.Y., Li W., Lv Z., Liu L., Tong M., Hai T., Hao J., Guo C.L., Ma Q.W., Wang L., Zeng F., Zhou Q. IPS cells produce viable mice through tetraploid complementation. Nature 2009, 461:86-90.
100. Zhao T., Zhang Z.N., Rong Z., Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.
101. Zilka N., Zilkova M., Kazmerova Z., Sarissky M., Cigankova V., Novak M. Mesenchymal stem cells rescue the Alzheimer's disease cell model from cell death induced by misfolded truncated tau. Neuroscience 2011, 193:330-337.